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Summary: Bipolar disorder (BD) used to be considered as a pure biological condition, 
with episodic course and good remissions. Nowadays long-term consequences and psycho­
social disturbances persisting beyond manic or depressive episodes have been recognized. 
Priory, acute phase treatment was the main target o f therapeutic strategics. Currently the 
maintenance treatment and prevention including periods of remission but beginning already 
in the acute phase became the most important aims o f BD treatment. The consequence o f such 
an approach is the inclusion of psychotherapy and social interventions in combination with 
phannacothcrapy. Psychotherapy enables achieving social recovery, relapse prevention as well 
as improvement o f compliance which determines largely the efficacy o f treatment. Cognitive 
-  behavioral therapy presents especially encouraging results in this field.
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Introduction
Since Kraepelin’s concept of manic-depressive illness as a psychotic illness with 
“endogenous” etiology, traditional approach to bipolar disorder (BD) has been largely 
biological. Indeed, there is compelling evidence for it’s biological etiology e.g. heri- 
tability rate for BD is only comparable to autism and attention-deficit/hyperactivity 
disorder (ADHD) [1], Unfortunately, as a consequence of the biological approach, a 
bipolar patient has been classified as a bad candidate for psychotherapy either due to 
poor insight, strong or excessive dependence on clinician or due to symptoms specific 
to acute manic phase like poor concentration, distractibility, labile mood etc. While 
research in neurobiology is central to understanding of BD, psychosocial research 
appears to be equally vital. Given the emerging realization that mind and brain are not 
different entities belonging to different realms of experience and growing acceptance for 
the vulnerability-stress model, the distinction between the biological and psychosocial 
aspects of illness -  which is the heritage of the reductionistic Cartesian dualism - begins 
to break down. Both -  medication and psychotherapy are acting through the same final 
common pathway -  the brain. This view is supported by recent work in obsessive-
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compulsive disorder (OCD), where behaviour therapy was shown to produce similar 
changes in PET neuroimaging as did medication treatment, leading Baer to suggest 
that behaviour therapy may be a form of "endogenous serotonin therapy” [2],
Rationale for combined treatment of BD
According to clinical data concerning a variety of problems related to bipolar di­
sorder there are five main reasons for combined treatment: 1 .Influence of life events 
and regular rhythm of life routine, 2.Unsatisfactory results of pharmacotherapy, 3.Co­
morbidity, 4. Non-compliance, 5.Complexity of BD.
Influence of life events and regular rhythm of life routine
It has been proven, that influence of life events and regularity of everyday life 
routine play an important role in the period prior to the onset of a bipolar episode. 
Disruption of sleep and routine can lead to deregulation of circadian rhythms and the 
motivational system, resulting in prodromal symptoms. Disrupted social rhythm sig­
nificantly increases risk of manic episode [3]. Factors like unstable working schedule, 
disruptions of circadian rhythms or long distance travel -  especially those connected 
with jet lag -  hold mania inducing potential [4], The exact nature of life events and 
social disruptions may determine the specific prodromal symptoms that occur -  events 
involving goal attainment are associated with the development of manic symptoms 
[5], whereas negative life events, low social support and low self-esteem predict the 
development of depressive symptoms [6]. Since life events and regular life rhythm 
are surely not biological in nature, there is a clear indication for combining pharma­
cotherapy with psychosocial interventions.
Unsatisfactory results of pharmacotherapy
Studies in the 1960’s and 1970’s suggested that lithium was an effective form of 
prophylaxis in BD treatment. However, reviews of more recent randomised controlled 
double-blind trials of mood stabilisers have suggested that these medications are not 
as effective at preventing relapse as initially reported [7]. There are still relatively 
high rates of relapse. 40% of bipolar patients relapse in one year [8], and only one 
third of bipolar patients achieve full symptomatic remission. Lifetime relapse rates 
for bipolar I and II are respectively as high as 72.9% and 60% [9], Furthermore, a 
significant proportion of patients with BD do not seem to benefit from mood stabilising 
medication with lithium either because of inadequate response or poor compliance due 
to side effects. Although further research trials are required to assess efficacy of other 
medications as carbamazepine and valproate, their efficacy appears to be similar to 
that of lithium [7]. It is worth noting that combined medication i.e. lithium plus other 
mood stabiliser such as carbamazepine or valproate appears superior to monotherapy 
in achieving prophylaxis [10, 11, 12]. Nonetheless there are still relatively high rates 
of relapse on combined medication. For example, Denicoff et al [11] reported that 
combined lithium and carbamazepine had some success in only 50% of patients with 
rapid-cycling BD. Despite advances in the pharmacologic treatment of bipolar disorder,
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it is clear that additional strategies are needed to provide patients with longer-term 
mood stability.
Comorbidity
Bipolar disorder is a highly comorbid condition. In the National Comorbidity Sur­
vey, all identified bipolar I individuals suffered from at least one, and often up to three 
or more, comorbid disorders [12]. The most common comorbid disorders include the 
full range of anxiety disorders, substance use disorders, and personality disorders. The 
estimates of comorbidity in BP vary among studies due to use of various criteria and 
diagnostic tools as well as populations studied (general, out-and/or inpatient). Reported 
lifetime prevalence of alcohol and drug abuse/ dependence in BP subjects range from 
21 to 69% [13, 14, 15, 16, 17, 18]. The estimates of lifetime anxiety comorbidity are 
similarly high and range from 24 to 61% [19, 20, 21]. The most common comorbid 
anxiety disorders in majority of studies are panic disorder with or without agoraphobia 
and OCD. The reported prevalence for social phobia, generalized anxiety disorder and 
post traumatic stress disorder are also elevated in many studies. Moreover for catego­
rically defined personality disorders the prevalence range can exceed 60% [22].
Comorbidity has been associated with suicidality, higher relapse rate, younger age 
at onset of affective symptoms, more depressive episodes, more mixed features, more 
severe episodes, poorer compliance, rapid-cycling, more hospitalizations, resistance 
to pharmacotherapy and lower Global Assessment of Functioning Scale (GAF) scores 
across studies [23, 24].
Psychotherapy proved it’s effectiveness in majority of the mentioned disorders, 
thus regarding the fact that the presence of comorbid conditions appears to be the rule 
rather than the exception in people with BD, there is a clear indication for combined 
psychosocial treatment.
Noncompliance
Nonadherence to treatment has been identified as a frequent cause of recurrence 
or relapse of bipolar disorder [25, 26]. Recent reports show, that one in three persons 
with bipolar disorder fail to take at least 30% of their medication [27]. Even among 
those receiving outpatient treatment, as many as 75% have been found to experience 
disruptions in consistent medication maintenance within a 1 -year period [28]. General 
prevalence of nonadherence with mood stabilizers ranges from about 18% to 52% [29]. 
These issues are particularly important to address, because poor medication adherence 
is one of the most robust predictors of hospitalization as well as suicide [30, 31 ].
High rates of nonadherence are common to many medical treatments. However 
some issues may be specific to bipolar disorder. One of the most important problems 
occurring in the course of treatment of the manic episode is a patient’s inclination 
to refuse medication due to a feeling of being deprived of happiness and power. In 
this case symptomatic improvement results in the lack of motivation for treatment. 
Simultaneously impaired motivation for treatment characterizes depressed patients.
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However in a depressive episode, it is one of the core symptoms of disease. Since 
other factors -  like side-effects -  commonly contribute to treatment rejection in BD, 
promotion of treatment adherence must be integrated into medication management of 
bipolar illness if  optimum outcomes are to be achieved [32],
ComplexityBD is a biological disorder with non-biological, long-lasting conse­
quences, It grossly interferes with many areas of life. Its common negative conse­
quences are: 1, Global impairment of life quality, 2, stigmatization in work and family, 
3, social isolation, 4, guilt and decreased self esteem resulting in hopelessness, 5, 
demoralization and dramatically increased suicidality. Since medication influences 
those areas only indirectly and non-specifically, again psychotherapy is strongly 
recommended.
Life quality of bipolar patients is significantly worse than among monopolar sub­
jects, Most mental health consumers report stigma from family members, employers 
and even within their religious organization [33], Hence, isolation and self esteem 
consequences of this disorder are very important [1],
One third of individuals remain unemployed a full year after hospitalization for 
mania [34], BD is projected to become the sixth leading medical cause of disability- 
adjusted life years worldwide by the year 2020 [35], Regarding high relapse rates and 
the difficulties in maintaining unemployment and social relationships, it is not sur­
prising that hopelessness and demoralization are common in this population. Suicide 
rates reaching 0,4% per year in men and women diagnosed with bipolar disorder are 
over 20-30 times higher than in the general population [8, 9, 36],
Treating BD with medication alone appears to be only a partial solution. Even an 
unquestionable upgrade of drug treatments does not ensure good social outcomes, co­
ping with subsyndromal symptoms and sufficient maintenance management. Effective, 
long-term approach requires pharmacological and non-pharmacological treatments 
combined with therapeutic alliance that facilitates a proactive, preventive approach 
to the illness [37],
Non-pharmacological strategies in the treatment of bipolar disorder
Various psychotherapeutic approaches have been conducted with bipolar patients. 
They are primarily psychoeducational and cognitive-behavioral although research 
has been done with family therapy, marital therapy, cognitive-behavioral therapy, 
interpersonal and social rhythm therapy, behavioral family management therapy and 
interpersonal therapy, either in individual and group mode [38, 32, 39], Researches 
on effectiveness of psychotherapy in BD are still in their infancy, however, a range 
of them appears to benefit people with bipolar disorder. Among the mentioned ap­
proaches cognitive-behavioral therapy (CBT) deserves attention for a few pragmatic 
reasons: it shares the characteristics of a clinically effective short-term psychological 
intervention [40] and it impacts on symptoms, social functioning and risk of relapse 
[41], CBT is also one of best researched approaches so far. Other interventions (exc­
luding psychoeducation) do not appear to be supported by sufficient evidence [42], 
Furthermore, therapies based on teaching patients new coping skills, like cognitive
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therapy, may be particularly appropriate for bipolar disorder according to recent 
evidence that particular coping skills and behavioral responses are important in the 
course of bipolar illness [7].
Cognitive-behavioral therapy of BD
CBT is based on an assumption that thinking, mood and behavior influence each 
other reciprocally. Therefore the therapist teaches patients to develop awareness of 
their thoughts, moods and behaviors in order to alter those thoughts and behaviors 
that are dysfunctional. Combination of thoughts monitoring and behavioral change 
is complementary to the psychosocial research on prodromes and routine in patients 
with BD, indicating that CBT may be a useful approach in such cases [7]. CBT for 
bipolar disorder has been conceptualized as an adjunct to medication rather than as a 
replacement for it. Furthermore, it has been designed as a relapse prevention treatment, 
not as an acute treatment, thus attempts to modify CBT for BD have concentrated 
on working with relatively euthymic patients outside of major depression or manic 
episode [7].
The main goals of cognitive-behavioral therapy in patients with bipolar disorder 
are: 1. To facilitate acceptance of the disorder and the need for treatment; 2. to help the 
individual to recognize and manage psychosocial stressors and interpersonal problems; 
3. to improve medication adherence; 4. to teach coping strategies for depression and 
hypomania; 5. to teach early recognition and monitoring of relapse symptoms and 
specific to them coping techniques; 6. to improve self management through home­
work assignment and 7. to identify, monitor and modify negative automatic thoughts 
and underlying maladaptive assumptions and beliefs; 8. to develop structured daily 
schedules [43, 44, 45].
The number of reports on the efficacy of adding either individual or group CBT 
to medication in BD is still not numerous yet continuously growing. Over the past 
twenty five years small group studies and case reports were published. Many resear­
chers [46, 43, 47, 48, 49, 50] have reported that combined cognitive-behavioral and 
pharmacological treatment produced significantly reduced relapse in comparison to 
routine mood stabilizing treatment. In 1984 Cochran reported that patients receiving 
group cognitive therapy had significantly fewer hospitalizations and were more adherent 
to lithium therapy than standard clinical care group. The patients were randomized, 
however, the principal limitation of the study was small sample size (n=28). [36]. In 
the study by Fava et al CBT proved it’s effectiveness in reducing of residual sympto- 
mathology and enhancing lithium prophylaxis in a group of bipolar I patients (a 2- to 
9-year follow-up; n= 15) [39]. Scott et al [50] in a 42-patient randomized pilot study 
examined the effect of 20 sessions of cognitive therapy (CT). At 6-month follow-up, 
subjects allocated to the cognitive therapy group showed statistically significantly 
greater improvements in symptoms and functioning as measured on the Beck Depres­
sion Inventory, the Internal State Scale, and the Global Assessment of Functioning 
than those in control group. 70% of subjects from the therapy group viewed CT as 
highly acceptable. Though encouraging, these studies had small sample sizes, such
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that any conclusion from them needs to be tentative [7]. Perry et al in a single blind 
randomized controlled trial with a larger sample (n=68) of bipolar remitted patients 
proved, that patients who learned to identify early symptoms of relapse and seek 
prompt treatment from health services had significantly fewer manic relapses and days 
in hospital than control subjects. Moreover they presented significantly higher levels 
of social functioning and better work performance. However, this trial was of more 
psychoeducational than cognitive-behavioral nature and had no significant impact on 
depression, therefore researchers suggested that more formal cognitive therapy may 
be important in producing significant changes in this area. [51]. Lam et al [52] have 
reported that combining of routine mood stabilizing medication with cognitive therapy 
significantly reduces relapse rates in bipolar patients in comparison to mood stabilizers 
alone. More recently, a full-scale randomized controlled trial of cognitive therapy for 
bipolar disorder has been completed [52]. 103 patients with bipolar I disorder were 
randomized either to treatment-as-usual group or to combined therapy (medication + 
CBT) group. At 12 months the combined therapy group comparing to treatment-as-usual 
group had significantly fewer bipolar episodes reflected by cumulative relapse rates 
(44% vs. 75%); fewer days in bipolar episodes (27 vs. 88); fewer hospitalizations and 
were more adherent to treatment [52]. That trial was continued and in the follow-up 
phase of the study [53] the cognitive therapy group had a significantly better outcome 
characterized by longer time to relapse, however the effect of relapse prevention ap­
peared mainly in the first year. The cognitive therapy group also spent fewer days in 
bipolar episodes. Multivariate analyses of variance showed that those patients exhibited 
significantly better mood ratings, social functioning, coping with bipolar prodromes, 
and dysfunctional goal attainment cognition [53].
Conclusion
Combination of psychotherapy and pharmacotherapy appears successful in allo­
wing bipolar patients to achieve better symptomatic and functional recovery as their 
therapeutic goals are complementary. A growing body of evidence documents the value 
of structured psychotherapeutic interventions for the co-management of BD in the 
context of ongoing medication treatment. Preliminary results regarding effectiveness of 
cognitive-behavioral therapy in the treatment of bipolar disorder are encouraging and 
indicate that CBT has particular characteristics that may benefit bipolar patients. It’s 
collaborative, stepwise approach may be helpful in increasing compliance, improving 
quality of life and functioning, early symptoms recognition, decreasing depressive 
symptomatology, number of hospitalizations and risk of relapse. To improve medi­
cation compliance and to help patients to identify prodromes of relapse it should be 
considered early in the course of illness. Still more precise, larger-scale and rigorous 
randomized clinical trials are needed to confirm the short-term and long-term effica­
cy of CBT in bipolar disorder. Understanding of cognitive processes specific for BD 
is necessary in order to allow us to refine and develop techniques and interventions 
unique for this disorder.
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